- Buprenorphine was the only approved medication for opioid use disorder (MOUD) that was significantly associated with a decrease in opioid-related overdose deaths among commercially insured patients with opioid use disorder (OUD).
Why this matters
- Opioid overdose deaths in the United States increased 28% between 2015 and 2016.
- Oral naltrexone, extended-release injectable naltrexone (XR-NTX), and buprenorphine are FDA-approved for OUD, but which is the most effective is unclear.
- Study of 46,846 commercially insured patients with OUD between 2010 and 2016.
- Funding: National Institute on Drug Abuse.
- Rate of opioid-related overdose was 4.98 overdoses per 100 person-years in patients who received no treatment, and 2.08 overdoses per 100 person-years in those who received buprenorphine.
- Patients receiving buprenorphine therapy had significantly lower risk for overdose vs no treatment (aHR, 0.40; P<.01>
- Current treatment with either XR-NTX or oral naltrexone was not protective against overdose (aHR, 0.74 [P=.31]; aHR, 0.93 [P=.60], respectively).
- Use of another substance use disorder was associated with an increased risk for overdose: alcohol (aHR, 1.33; P<.01 cannabis p cocaine and sedatives>
- Retrospective design.
Coauthored with Antara Ghosh, PhD